ESR1 and breast cancer: Although combined inhibition of Bcl-2 and Bcl-xL using ABT-263 is capable of inducing apoptosis in ERɑ+ breast cancer cells [17], rapid Mcl-1 upregulation in response to ABT-263 limits the extent to which apoptosis is induced in these cells.